BACKGROUND: Few large, prospective, randomized studies have investigated the effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma (TESCC) who receive definitive radiotherapy (RT) or concurrent chemoradiotherapy (CCRT) through modern, intensity modulated-RT (IMRT) techniques. The therapeutic effects of esophagectomy in patients with TESCC were evaluated using modern clinical staging and RT techniques and suitable RT doses. METHODS: The authors analyzed data from patients with TESCC from the Taiwan Cancer Registry database. Patients were categorized into the following groups on the basis of treatment modality to compare their outcomes: group 1 received definitive CCRT, group 2 received neoadjuvant RT followed by esophagectomy (total IMRT dose, 50 grays [Gy]), and group 3 receiving neoadjuvant CCRT followed by esophagectomy (total IMRT dose, 50 Gy). The median total RT dose and fraction size were 50.4 Gy and 1.8 Gy per fraction, respectively. Group 1 was used as the control arm for investigating the risk of mortality after treatment. RESULTS: In total, 3123 patients who had TESCC without distant metastasis were enrolled. Patient ages 65 years and older, Charlson comorbidity index scores 3, advanced clinical stages (IIA-IIIC), alcohol consumption, and cigarette smoking were identified as significant, independent poor prognostic risk factors for overall survival in multivariate Cox regression analyses. In group 3, after adjustment for confounders, the adjusted hazard ratios (95% confidence intervals 
INTRODUCTION
The majority of esophageal cancers are squamous cell carcinomas (SCCs) or adenocarcinomas. Although the incidence of esophageal SCCs has been decreasing in the United States, 1 that of esophageal SCCs has been increasing in some Asian countries like Taiwan, probably because of an increase in tobacco and alcohol consumption. 2 Esophageal cancer is the ninth most common cancer in Taiwan. 3 Greater than 90% of esophageal cancers in Taiwan are SCCs. 2 The 5-year overall survival rate for esophageal cancer was only 12.8% from 1998 to 2007 in Taiwan. 4 The management of carcinoma arising in the cervical or esophagogastric junction is very different from that of thoracic esophageal SCC (TESCC). [5] [6] [7] [8] [9] [10] [11] [12] [13] The management of cervical esophageal cancer is more closely related to the management of head and neck SCC than that of malignancies involving the more distal portions of the esophagus. Concurrent chemoradiotherapy (CCRT) is preferred over surgery in patients who have cervical esophageal cancer, because survival appears to be the same with both treatments, and major morbidity is avoided in most patients. 7, [10] [11] [12] [13] By contrast, complete surgical resection is the first treatment choice in the management of cancer of the esophagogastric junction. 5 Furthermore, combinedmodality therapies including CCRT, surgery, and neoadjuvant radiotherapy (RT) or CCRT are used in the management of TESCC followed by surgery. [14] [15] [16] [17] However, treatment modalities for the optimal management of patients with TESCC remain controversial.
At least 2 randomized trials directly comparing definitive CCRT alone versus trimodality therapy (neoadjuvant CCRT followed by surgery) have failed to demonstrate improved survival; nevertheless, both of those trials reported more satisfactory locoregional control and a reduced need for palliative procedures when surgery was included as a component of multimodality therapy. 15, 16 However, those trials included patients who had esophageal adenocarcinoma, used old RT techniques and various RT doses and fraction sizes, and did not provide accurate information regarding esophageal portions. 15, 16 Few large, prospective, randomized studies have investigated the effectiveness of esophagectomy in patients with TESCC who receive definitive RT or CCRT through modern, intensity-modulated RT (IMRT) techniques. The effects of esophagectomy require further investigation using modern clinical staging and techniques (and probably concurrent chemotherapy [CT] ) to determine the most appropriate therapy for patients with TESCC. In this study, we evaluated the therapeutic effects of esophagectomy in TESCC using modern clinical staging, modern RT techniques, and suitable RT doses.
MATERIALS AND METHODS
In this study, we established a cohort using data from the Taiwan Cancer Registry database. We enrolled patients who received a diagnosis of TESCC between January 1, 2006, and December 31, 2014. The follow-up duration was from the index date to December 31, 2014. The Cancer Registry database of the Collaboration Center of Health Information Application contains detailed cancerrelated information, including clinical stage, treatment modalities, pathology, radiation doses, RT techniques, and regimens used (CT, CCRT, or sequential CT and RT). [18] [19] [20] [21] Our protocols were reviewed and approved by the Institutional Review Board of Taipei Medical University. The diagnoses of enrolled patients were confirmed according to their pathologic data, and patients who received a new diagnosis of TESCC were confirmed to have no other cancer or distant metastasis. The inclusion criteria were TESCC, age 20 years, and American Joint Committee on Cancer (AJCC) clinical cancer stages I through III without metastasis. The exclusion criteria were a history of cancer before TESCC diagnosis, distant metastasis, unknown esophageal locations, missing sex data, age <20 years, unclear staging, and non-SCC histology. The index date was the date of TESCC diagnosis. TESCC was defined as esophageal SCC with pathologic proof in the thoracic area from the cancer registry database. In addition, we excluded patients with TESCC who did not receive any treatments, did not receive RT (50 grays [Gy]) after TESCC diagnosis, did not receive a cisplatin-based CT regimen, received sequential CT and RT, received CT alone, received RT alone, received an RT dose >60 Gy, received adjuvant therapy after esophagectomy or definitive CCRT, and underwent esophagectomy more than 12 weeks after RT or CCRT. We excluded those who had received neoadjuvant CT from the study, because only 8 patients who underwent received CT were reported in the database. Finally, we enrolled patients with TESCC and categorized them into the following groups on the basis of treatment modality to compare their outcomes: group 1 included those who received definitive CCRT, group 2 included those who underwent neoadjuvant RT followed by esophagectomy (total IMRT dose, 50 Gy), and group 3 included those who received neoadjuvant CCRT followed by esophagectomy (total IMRT dose, 50 Gy). The median total RT dose and fraction size were 50.4 Gy and 1.8 Gy per fraction, respectively. Comorbidity was scored using the Charlson comorbidity index (CCI). 19, 22 Only comorbidities observed 6 months before and after the index date were included; comorbid conditions were identified and included according to the main International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes for the first admission or more than 2 repeated main diagnosis codes for visits to the outpatient department. Significant, independent predictors, such as age, sex, CCI score, AJCC clinical stage, year of diagnosis, betel nut chewing, alcohol consumption, and cigarette smoking, were determined using a multivariate Cox regression analysis to determine the hazard ratio (HR); independent predictors were controlled for or stratified in the analysis, and the endpoint was the mortality rate among treatments, with group 1 as the control arm.
The cumulative incidence of death was estimated using the Kaplan-Meier method, and differences between treatment modalities were determined using the log-rank test. After adjustment for confounders, the Cox proportional-hazards method was used to model the time from the index date to all-cause mortality among patients who received the treatments. In the multivariate analysis, HRs were adjusted for age, sex, CCI score, clinical AJCC stage, year of diagnosis, betel nut chewing, alcohol consumption, and cigarette smoking. Stratified analyses were performed to evaluate the risk of mortality associated with different treatment modalities and with different AJCC clinical stages. All analyses were performed using SAS statistical software (version 9.3; SAS, Cary, NC). A 2-tailed P value < .05 was considered statistically significant.
RESULTS
We enrolled 3123 patients who had TESCC without distant metastasis (Table 1 ). Of these, 161 patients received neoadjuvant RT followed by esophagectomy, 869 received neoadjuvant CCRT followed by esophagectomy, and 2093 received definitive CCRT. The mean follow-up duration after the index date was 2.75 years (standard deviation, 2.15 years). Of the elderly patients (aged 65 years), many received definitive CCRT (24.51%) ( Table 1) , and few received neoadjuvant RT or CCRT followed by esophagectomy (16.77% and 13.23%, respectively). Moreover, 14.05% of patients who had CCI scores 3 received definitive CCRT; however, only 8.75% of those who had CCI scores 3 received neoadjuvant CCRT followed by esophagectomy. More patients Table 1) .
The multivariate Cox regression analysis indicated that age, CCI score, AJCC clinical stage, alcohol consumption, cigarette smoking, and receipt of neoadjuvant RT or CCRT followed by esophagectomy were significant, independent predictors (Table 2) . Furthermore, age 65 years, CCI scores 3, advanced clinical stage (IIA-IIIC), alcohol consumption, and cigarette smoking were identified as significant, independent poor prognostic risk factors for overall survival in multivariate Cox regression analysis (Table 2) . Neoadjuvant RT (adjusted HR [aHR], 0.66; 95% confidence interval [CI], 0.54-0.80) and neoadjuvant CCRT (aHR, 0.48; 95% CI, 0.44-0.54) followed by esophagectomy were significant, independent prognostic protective factors for overall survival (both P < .0001) ( Table 2) .
AJCC clinical stage was identified determined as a crucial, independent predictor. Furthermore, aHRs increased with advancing stages from stages IIA through IIIC (aHR: 1.14, 1.23, 1.32, 1.73, and 2.06 for stages IIA, IIB, IIIA, IIIB, and IIIC, respectively) ( Table 2) . Stratified analyses were performed to evaluate the risk of mortality among treatment modalities for different AJCC clinical stages, and a stratified Cox proportional-hazard model was used to analyze the risk of mortality associated with different treatment modalities among patients with (Table 3) . Kaplan-Meier overall survival curves for patients in the 3 treatment arms without AJCC stage stratification are provided in Figure 1 . The overall survival rate was the highest in group 3 (log-rank test; P < .0001). The 2-year overall survival rates were 27.43%, 38.84%, and 55.77% in groups 1, 2, and 3, respectively. Figure 1 also presents Kaplan-Meier overall survival curves for patients in the 3 treatment arms according to different clinical AJCC stages. Within the same AJCC clinical stage, the survival rate was higher in group 3 than in groups 1 and 2 (logrank test; P < .05). The 2-year overall survival rates in patients with clinical stages IIA, IIB, IIIA, IIIB, and IIIC disease were 38.94%, 38.77%, 30.12%, 22.74%, and 18.97%, respectively, in group 1; 64.73%, 30.34%, 46.35%, 26.44%, and 37.56%, respectively, in group 2; and 69.85%, 62.34%, 59.73%, 50.12%, and 49.68%, respectively, in group 3. However, the 2-year overall survival rate in patients with clinical stage I disease did not significantly differ among groups 1, 2, and 3 (log-rank test; P 5 .8482). Figure 2 presents the Cox proportionalhazard models adjusted for age, sex, CCI score, year of diagnosis, betel nut chewing, alcohol consumption, and cigarette smoking for patients in the 3 treatment arms. Compared with group 1, overall survival was more satisfactory in groups 2 and 3.
DISCUSSION
In contemporary series, definitive CCRT provided longterm survival in up to 27% of patients with TESCC or adenocarcinoma 14, 17, 23, 24 ; this finding is consistent with those reported in studies of neoadjuvant CCRT followed by esophagectomy and definitive CCRT. 15, 16 In general, data on the nonsurgical management of patients with TESCC are lacking, and only a retrospective series has suggested that outcomes were poor for patients who had esophageal adenocarcinoma treated with nonsurgical therapy. 25 A survival benefit has been suggested for trimodality therapy over CCRT in national surveys of patients with thoracic adenocarcinoma or SCC who were treated in the 1990s [26] [27] [28] and in an analysis of data from the National Cancer Database for patients with esophageal adenocarcinoma or SCC who were treated between 2004 and 2011. 28 However, those analyses included various RT doses, fraction sizes, and CT regimens; had unclear information regarding cervical or esophagogastric junction portions of the esophagus; included heterogenous pathologic types; used old RT techniques (non-IMRT); did not consider alcohol consumption, cigarette smoking, or betel nut chewing; and had various inclusion criteria. In the current study, we used a relatively homogenous RT dose (median, 50.4 Gy), included only patients who had TESCC, and used cisplatin-based regimens and IMRT techniques to evaluate the therapeutic effect of esophagectomy in patients with TESCC who received modern CCRT and standard doses.
Increasing numbers of studies have supported the view that esophageal SCC and adenocarcinoma differ in terms of pathogenesis, epidemiology, tumor biology, and prognosis. Histology also influences the pattern of first recurrence after treatment. 29, 30 TESCC tends to recur locoregionally first, whereas esophageal adenocarcinoma more commonly recurs with distant dissemination. 29, 30 Despite these data, many contemporary researchers have suggested that the prognosis of adenocarcinoma is more favorable than that of SCC. [29] [30] [31] [32] [33] [34] [35] One reason may be the lower prevalence of lymphatic spread in esophageal adenocarcinoma than in SCC. 29, 30 Some studies have suggested that induction CT alone is adequate for adenocarcinomas; however, neoadjuvant CCRT can be more suitable for SCCs because of the high need for tumor downsizing to achieve a complete radical resection. 30 Therefore, these findings indicate that SCC and adenocarcinoma differ in terms of pathogenesis, epidemiology, tumor biology, and prognosis, requiring different therapeutic strategies. 30 Siewert and Ott suggested that 2 different tumor entities should be analyzed and reported separately to provide comparable results in the future. 30 In our study, we included only patients with TESCC. To the best of our knowledge, this is the first study to investigate the effectiveness of esophagectomy in patients with TESCC who received definitive RT or CCRT through modern IMRT techniques.
The Radiation Therapy Oncology Group 85-01 and Intergroup 0123 trials have reported that high-dose RT (>60 Gy) is significantly more toxic. 14, 17 In our study, we enrolled patients with TESCC who received a median RT dose of 50.4 Gy to reduce the bias that a high dose might compromise the survival rate in patients with TESCC. Newer radiation techniques like IMRT have been associated with more favorable toxicity profiles. 36 In addition, pathologic response rates after CCRT were higher in patients with TESCC than in those with adenocarcinoma. 37 The necessity of esophagectomy in patients with TESCC who received definitive CCRT or RT with IMRT techniques remains controversial. 26 The overall survival rate was the highest in group 3 in our study, as indicated in Tables 2 and 3 . In addition, the mortality risk was the highest in group 1. These findings indicate that esophagectomy can be beneficial even in patients with TESCC who receive standard-dose IMRT. In 2 randomized trials, the local control rate was higher in patients who received trimodality therapy than in those who received CCRT alone; however, no survival benefits were reported. 10, 11 The local control rate could not be translated into survival benefits, because treatment-related mortality was higher in the trimodality arm (12.80% vs 3.50%). 16 The differences between the results from our study and those from those 2 randomized trials 10,11 might be attributable to reductions in the heart and lung toxicity caused by IMRT, potentially further reducing complications and mortality after esophagectomy. 36, 38 Because TESCC tends to recur locoregionally first, 29, 30 translation of the local control rate into a survival benefit would be promising in trimodality therapy with modern techniques if an optimal irradiation dose and modern techniques like IMRT can reduce treatment-related mortality.
The proportion of betel nut chewers, alcohol consumers, and cigarette smokers among the patients with TESCC was 61%, 87%, and 86.01%, respectively, as indicated in Table 1 . Cigarette smoking and alcohol consumption are major risk factors for TESCC in Asia and in Western countries. [39] [40] [41] [42] [43] Betel nut chewing, which is
Original Article widespread in some regions of Asia, has been implicated in the development of TESCC. 44, 45 However, few studies have reported prognostic factors for overall survival in patients with TESCC who received RT and had habits of betel nut chewing, alcohol consumption, or cigarette smoking. Age 65 years, CCI scores 3, advanced clinical stage (IIA-IIIC), alcohol consumption, and cigarette smoking were identified as significant, independent poor prognostic risk factors for overall survival in the multivariate Cox regression analysis, as indicated in Table 2 . Multivariate Cox regression analysis identified alcohol consumption and cigarette smoking as significant, independent poor prognostic factors for overall survival, with aHRs of 1.22 (95% CI, 1.16-1.29; P 5 .0018) and 1.21 (95% CI, 1.03-1.43; P 5 .0236), respectively.
To our knowledge, this is the first study to demonstrate that alcohol consumption and cigarette smoking are significant, independent poor prognostic risk factors for overall survival in patients with TESCC who receive RT. Nevertheless, betel nut chewing was not identified as a poor prognostic factor for overall survival in our study. Moreover, few studies are available on the safety and efficacy of definitive CCRT with or without esophagectomy in elderly patients. Our results suggest that, compared with younger patients, patients aged 65 years who received cisplatin-based CCRT had a significant increase in mortality (Table 2 ). In addition, the aHR was 1.05 (95% CI, 1.02-1.09; P 5 .0487) per additional year after age 50 years. The number of deaths was higher among patients who had significant comorbidities (CCI score 3) than among those without comorbidities; this finding was comparable to that of a previous study. 46 The 2010 AJCC staging system is compatible with our data. The aHRs of mortality increased with advancing stages (Table 2) .
A stratified Cox proportional-hazards model was used to analyze the mortality risk associated with different treatment modalities among patients with TESCC (Table  3) . After adjustment for age, sex, CCI score, clinical AJCC stage, year of diagnosis, betel nut chewing, alcohol consumption, and cigarette smoking, no significant differences were observed between groups 2 and 3 in patients who had AJCC clinical stage I disease. However, the reduction in mortality risk was evident, and aHRs tended to decrease with advancing AJCC clinical stage (IIA). These findings suggest that the necessity of esophagectomy after definitive CCRT increases with advancing clinical stages. Our results support the view that esophagectomy is necessary after definitive CCRT when the AJCC clinical stage is IIA. The survival rate was higher in group 2 (aHR, 0.66; 95% CI, 0.54-0.80) than in group 1 after adjustment for confounders (Table 3) . This finding may be attributable to the poorer survival of patients with TESCC versus those with adenocarcinomas, because TESCC tends to recur locoregionally first, whereas esophageal adenocarcinoma more commonly recurs with distant dissemination. [29] [30] [31] [32] [33] Therefore, compared with definitive CCRT, neoadjuvant RT followed by esophagectomy is more effective in achieving local control in TESCC. Taken together, compared with definitive CCRT and neoadjuvant RT followed by esophagectomy, neoadjuvant CCRT followed by esophagectomy provides more aggressive local control and reduces the possibility of distant metastasis. Therefore, the survival rate was higher in group 3 than in groups 1 and 2 ( Figs. 1 and 2) .
Our results suggest that neoadjuvant CCRT followed by esophagectomy can be more beneficial in clinical practice for patients with TESCC, particularly in those with advanced AJCC clinical stages (IIA). For patients with clinical stage I disease, definitive CCRT might be a feasible and favorable choice. However, for those with more advanced stages of TESCC (stage IIIA-IIIC), definitive CCRT is not an ideal therapy. Moreover, compared with definitive CCRT, neoadjuvant CCRT followed by esophagectomy can reduce the mortality rate by greater than 50% (Table 3) . In another study (data not published), we analyzed survival rates after trimodality therapy and esophagectomy and observed that surgery alone was not adequate in patients who had advanced AJCC stages (IIIA-IIIC).
This study had some limitations. First, toxicity induced by the 3 different treatments could not be determined; therefore, treatment-related mortality estimates may have been biased. Second, information regarding pathologic risk factors and response rates after RT or CCRT was not recorded in the database used for this study; hence, the effects of various treatments on different response rates or pathologic risk factors could not be examined. Nevertheless, we used the definitive CCRT-only group as the control arm, and clinical data were compared among the 3 arms, because no pathologic risk factors were present in the definitive CCRT group. If more pathologic risk factors were present or poor response rates were obtained in groups 2 or 3, then the survival benefit would be underestimated. This indicates that the overall survival benefit might be stronger because physicians might consider incomplete responses after esophagectomy. Third, because all patients with TESCC were enrolled from an Asian population, the corresponding ethnic susceptibility remains unclear; hence, our results should be cautiously extrapolated to non-Asian populations. Fourth, the stratification of a relatively low number of patients receiving neoadjuvant RT followed by esophagectomy after staging might limit the generalizability of our conclusions. Fifth, diagnoses of all comorbid conditions were completely dependent on codes from the International Classification of Diseases, Ninth Revision, Clinical Modification. Nevertheless, the Taiwan Cancer Registry Administration randomly reviews charts and interviews patients to verify the accuracy of the diagnoses, and hospitals with outlier chargers or practices may undergo an audit and subsequently receive heavy penalties if malpractice or discrepancies are identified. Sixth, to prevent the creation of several subgroups, various surgical procedures were not categorized separately during analyses. Thus, the effects of different surgical procedures remain unclear. Seventh, planned esophagectomy might be difficult because of poor response of definitive CCRT. A possible selection bias in the study might be definitive CCRT to relatively huge and unresectable TESCC with poor response within the same clinical stages. Therefore, to obtain crucial information concerning population specificity and disease occurrence, a large-scale, randomized trial comparing carefully selected patients who receive suitable treatments is essential. Finally, the Cancer Registry Database does not contain information regarding dietary habits, socioeconomic status, or body mass index, all of which may be risk factors for mortality. However, considering the magnitude and statistical significance of the observed effects in this study, these limitations are unlikely to affect the conclusions.
Conclusions
Esophagectomy can be beneficial in patients with TESCC after definitive CCRT, especially in those with advanced AJCC stages. Age 65 years, CCI scores 3, advanced clinical stages (IIA-IIIC), alcohol consumption, and cigarette smoking are significant, independent, poor prognostic risk factors for overall survival in patients with TESCC.
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